The Institute for Clinical and Economic Review (ICER) released a report this week that highlighted seven pharmaceuticals with “substantial price increases on top of already high current spending.” According to ICER, these seven agents accounted for billions in unnecessary expense in 2017 and 2018. AbbVie’s Humira® and Genentech’s Rituxan® topped the list, with Neulasta® coming … Continue reading Biosimilar Bytes This Week
Tag: price increases
$7.6 Billion Estimate on Savings Lost From Approved, Nonlaunched Biosimilars Could Be Low
$44 Billion by 2024. $250 Billion by 2024. Whatever. I’ve not been very impressed by the many attempts to estimate how much money biosimilars could save the US health care system. Even the more well-known estimates of biosimilar savings, like those from RAND and Express Scripts, have been little more than games of "pin the … Continue reading $7.6 Billion Estimate on Savings Lost From Approved, Nonlaunched Biosimilars Could Be Low
Let’s not Knock Innovation, but Biosimilars Exist for the Sake of Competition
A recent Twitter conversation between a blogging colleague of mine and a German advocate of precision medicine propelled this post: What is the real benefit of biosimilars? Does biosimilar development detract from efforts to produce innovative medicines? Is the main societal benefit biosimilar cost savings? Biosimilar Development Is Separate From Innovation Development The main reason … Continue reading Let’s not Knock Innovation, but Biosimilars Exist for the Sake of Competition
Teva’s Syprine Generic Priced 14% Below Jacked Up Valeant Product Price
In an announcement that surprised few, Teva Pharmaceuticals announced that its generic version of trientine hydrochloride (Syprine®) for the treatment of Wilson’s disease will be sold for a very nongeneric price. Also unsurprising, Teva executives did not address the fact that the price of Syprine had been jacked up astronomically by Valeant Pharmaceuticals only recently, … Continue reading Teva’s Syprine Generic Priced 14% Below Jacked Up Valeant Product Price
What Will Cost Savings on 2023 Adalimumab Biosimilars Really Be Worth?
AbbVie executives are sticking to their pledge to restrict annual price increases on Humira® below 10%, but even payer price protections won’t mitigate the increasing expenditures before adalimumab biosimilars hit the market. In 2023, when adalimumab biosimilars become available, the savings biosimilars represent may not be real savings at all. Pharmaceutical companies generally seek to … Continue reading What Will Cost Savings on 2023 Adalimumab Biosimilars Really Be Worth?